Ori lands $120M deal for automated cell therapy manufacturing platform
The pact signals growing commercial demand for automated cell therapy production even as another key player in the niche faces a setback.
Ori, a company focused on automated cell therapy manufacturing, has locked down a $120 million pact to deploy its automated production platform for a commercial cell therapy. The therapy itself and the partner involved have not been disclosed, according to Fierce Pharma.
The deal places Ori in a contrasting position to another key player in the automated cell therapy manufacturing space that is currently grappling with a recent setback. Despite that turbulence, Ori's commercial agreement suggests that automated production platforms remain attractive to cell therapy developers looking to scale manufacturing.
With only one source, there is no conflicting reporting to compare. The news, as presented, highlights both the promise and the uneven landscape of automated cell therapy manufacturing.
More in Medicine & Biotech
Ebola Vaccine Trial Launches in DR Congo Outbreak Zone
Health workers in DR Congo have begun testing whether a vaccine designed for a different Ebola strain can protect against the current outbreak.
Beacon Gene Therapy for Rare Vision Loss Succeeds in Pivotal Trial
A pivotal trial of Beacon Therapeutics' gene therapy for X-linked retinitis pigmentosa improved visual acuity, clearing the path toward an FDA submission.
Alkermes orexin agonist shows early promise for ADHD
Early-stage data suggest Alkermes' orexin agonist could expand the drug class beyond sleep disorders into ADHD.
Telix to Buy ITM for $1.65B, Challenging Novartis in Radiopharma
The acquisition gives Telix a late-stage pipeline and supply network that could compete with Novartis' Lutathera.